Physician profile
Joel Wise
NPI 1548752744
$3,351.94
in general payments reported to CMS, 2019-2025
45 companies · $900 in 2025
The $900 reported for 2025 was more than what 88% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $468 · 2022: $515 · 2023: $555 · 2024: $914 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $479.79 | 2021-2025 | Krystexxa, Evenity, Otezla |
| Otsuka America Pharmaceutical, INC. | $387.52 | 2021-2025 | Rexulti |
| Abbvie INC. | $299.07 | 2022-2025 | |
| Lilly USA, LLC | $264.26 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.32 | 2021-2024 | Jardiance |
| Mimedx Group, INC. | $149.05 | 2024-2025 | |
| Kerecis Limited | $142.91 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Scilex Pharmaceuticals INC. | $134.25 | 2022-2023 | Ztlido |
| Glaxosmithkline, LLC. | $95.83 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Convatec INC. | $88.46 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $69.73 | 2022-2024 | |
| Mylan Specialty L.P. | $65.53 | 2021-2023 | Yupelri |
| Horizon Therapeutics Plc | $64.70 | 2023 | Krystexxa |
| Vertex Pharmaceuticals Incorporated | $57.72 | 2025 | |
| Bard Peripheral Vascular, INC. | $54.27 | 2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $51.29 | 2021 | |
| Novo Nordisk INC | $49.24 | 2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $43.98 | 2022-2023 | Verquvo, Recarbrio, Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.87 | 2023-2024 | Xifaxan |
| Tactile Systems Technology INC | $39.57 | 2021-2024 | Entre Plus, Flexitouch Plus |
| Exact Sciences Corporation | $38.77 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $35.38 | 2021 | |
| Lundbeck LLC | $34.99 | 2025 | Vyepti |
| Ani Pharmaceuticals, INC. | $31.87 | 2025 | Purified Cortrophin Gel |
| Averitas Pharma INC. | $29.52 | 2023 | Qutenza |
| Abbott Laboratories | $28.55 | 2023-2025 | Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $28.15 | 2021-2024 | Airsupra |
| Teva Pharmaceuticals USA, INC. | $26.04 | 2024 | Austedo Xr |
| Hartmann USA, INC. | $25.53 | 2025 | Zetuvit Plus 10x10 P10 |
| Melinta Therapeutics, LLC | $24.38 | 2021-2022 | |
| Eisai INC. | $24.13 | 2024 | |
| Biogen, INC. | $23.79 | 2025 | Skyclarys |
| Viatris Specialty LLC | $23.56 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $22.15 | 2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.06 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $19.62 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $18.40 | 2025 | |
| Medtronic, INC. | $15.15 | 2024 | Minimed 780g |
| Pfizer INC. | $13.80 | 2024 | |
| Urgo Medical North America, LLC | $13.53 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Takeda Pharmaceuticals U.S.A., INC. | $13.28 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.84 | 2022 | |
| Sonex Health, INC. | $11.80 | 2023 | Sx-One Microknife |
| Genentech USA, INC. | $11.27 | 2021 | |
| Organon LLC | $10.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.